ROADS Phase 3 Clinical Trial Data Presented at ASCO26 Show GammaTile® Provides Superior Tumor Control Leading to Patients Living Longer Without Recurrence Compared to Standard of Care in Newly Diagnosed Operable Brain Metastases ...Middle East

Results support GammaTile (cesium-131 collagen tile-based radiation therapy, or TBRT) as a new standard of care for achieving optimal outcomes in this patient population Superior efficacy achieved without increased side effects Data presented in late-breaking abstract at the 2026 Annual...

Hence then, the article about roads phase 3 clinical trial data presented at asco26 show gammatile provides superior tumor control leading to patients living longer without recurrence compared to standard of care in newly diagnosed operable brain metastases was published today ( Saturday 30/05/2026 - 03:09 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( ROADS Phase 3 Clinical Trial Data Presented at ASCO26 Show GammaTile® Provides Superior Tumor Control Leading to Patients Living Longer Without Recurrence Compared to Standard of Care in Newly Diagnosed Operable Brain Metastases )

Also on site :

• Art Garfunkel Makes Surprise Return to Madison Square Garden with Charlie Puth in Special Performance of "The Boxer"
• The Coronation Of Santa Maria’s 2026 Rodeo Queen
• EU and NATO pushing Romania toward war with Russia – MEP